1 / 27

The International CardiOncology Society An Update for 2014

The International CardiOncology Society An Update for 2014. Daniel J Lenihan , MD Professor, Division of Cardiovascular Medicine Director, Clinical Research Vanderbilt University. The International CardiOncology Society An Update. Exactly what does this society mean?

raphael-powell
Download Presentation

The International CardiOncology Society An Update for 2014

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The International CardiOncology Society An Update for 2014 Daniel J Lenihan, MD Professor, Division of Cardiovascular Medicine Director, Clinical Research Vanderbilt University

  2. The International CardiOncology SocietyAn Update • Exactly what does this society mean? • How do we do things? • What are our goals? • How do we achieve them? • Is there really a future for this?

  3. ICOS is: • A collection of interested providers focused on improving cardiac health in cancer patients • A mix of academic, practice, governmental, regulatory, and industry professionals • Committed to our patients wherever they are

  4. The International CardiOncology SocietyAn Update • Exactly what does this society mean? • How do we do things? • What are our goals? • How do we achieve them? • Is there really a future for this?

  5. We do things in many ways: • Day to day improvement in our practices • Monthly webinars available to all • Periodic presentations at major meetings • Annual ICOS congresses • Development of current “Best Practice” • Data review for ongoing early phase and late phase clinical trials • Ongoing participation in major professional society efforts • Ongoing individual and multicenter research • Consistent involvement with regulatory agencies in many countries

  6. The International CardiOncology SocietyAn Update • Exactly what does this society mean? • How do we do things? • What are our goals? • How do we achieve them? • Is there really a future for this?

  7. ICOS goals • Research • Engage large databases • Cardiac safety endpoint adjudication • Hypothesis testing research • Advocacy • Patients/families • Providers • Education • Provider case review • Patient directed • Professional meetings • Industry/regulatory webinars • Trainee organization • Be a Resource • Up to Date information • Identify Goals for the future • Provide innovation • Be an example of collaboration

  8. Number of PUBMED articles on Cardio-Oncology 1971 2014

  9. www.oncoreview.pl

  10. The International CardiOncology SocietyAn Update • Exactly what does this society mean? • How do we do things? • What are our goals? • How do we achieve them? • Is there really a future for this?

  11. PREDICT Study: A multicenter study in Patients undergoing anthRacycline-based chemotherapy to assess the Effectiveness of using biomarkers to Detect and Identify Cardiotoxicity and describe Treatment Daniel J Lenihan, MD Professor, Division of Cardiovascular Medicine Vanderbilt University CCOP Annual Meeting 2010

  12. Total Accrual: 597 patients

  13. In the case of HER2+ breast cancer, treatment clearly benefitted the disease but came at a cost Slamon D et al; NEJM 2011:365:1273-83

  14. The effect of time for initiation of HF therapy and the percent of patients who improve 100 64% 80 60 Responders (%) 28% 40 7% 20 0% 0% 0% 0% 0 1-2 2-4 8-10 4-6 6-8 >12 10-12 months (n=35) (n=75) (n=20) (n=12) (n=8) (n=44) (n=7) D Cardinale, et al. JACC 2010, jan 26.

  15. In regards to Ischemic insults, we have a paradigm Kloner et al, Circ 2001; p2981

  16. Statin therapy prior to and during chemotherapy was protective JACC 2012, p 2384

  17. Prevention of Cardiotoxicity is possible Bosch, X et al, JACC 2013, p 2355

  18. Are there things on the cancer therapy horizon that could be concerning for cardiomyopathy?

  19. There is a balance between protein synthesis and degradation Monte S. Willis, M.D., Ph.D., and Cam Patterson, M.D., M.B.A. NEJM 2013;368:455-64.

  20. Dick,LR and Flemming,PE Drug Discovery Today ;15 (5/6) March 2010

  21. The International CardiOncology SocietyAn Update • Exactly what does this society mean? • How do we do things? • What are our goals? • How do we achieve them? • Is there really a future for this?

  22. A Paradigm for Cardiology Oncology Cooperation Kouri M et al. Circulation 2012

  23. ICOS= A public, private, patient, provider, regulatory, governmental PARTNERSHIP

  24. www.icosna.org

More Related